-
-
-
-
-
-
-
Horizon Therapeutics' (HZNP) Tepezza Sales Rebound in April, Commentary from the Jefferies Healthcare Conference
-
-
-
-
-
-
-
Horizon Therapeutics (HZNP) PT Raised to $55 at Jefferies on Increased Tepezza Uptake
-
-
-
-
-
-
-
Horizon Pharma (HZNP) PT Raised to $21 at Jefferies; Reiterates Buy
-
-
-
-
-
-
-
An Important Win for Horizon Pharma (HZNP) - Jefferies
-
-
-
-
-
-
-
Horizon Pharma (HZNP) Raises Prices on Several Products - Jefferies
-
-
-
-
-
-
-
Notable Analyst Rating Changes 11/23: (CMG) (JRVR) (PBF) Upgraded; (TXTR) (CTCT) (CAVM) Downgraded
-
-
-
-
-
-
-
Horizon Pharma plc Proposes to Acquire Depomed, Inc. for $29.25 per Share in an All-Stock Transaction, Representing a 42 Percent Premium to Depomed's Shareholders
-
56,504 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All